Lixia Diao

List of Publications by Year
in descending order

104 **papers**	12,709 **citations**	44069 48 **h-index**	31849 101 **g-index**
109 **all docs**	109 **docs citations**	109 **times ranked**	20736 **citing authors**

#	Article	IF	Citations
1	GPEdit: the genetic and pharmacogenomic landscape of A-to-I RNA editing in cancers. Nucleic Acids Research, 2022, 50, D1231-D1237.	14.5	16
2	Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. Molecular Cancer Research, 2022, 20, 280-292.	3.4	4
3	Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. , 2022, 10, e003779.		34
4	Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. Journal of Experimental and Clinical Cancer Research, 2022, 41, 109.	8.6	7
5	The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8+ cytotoxic T-cell response. Genes and Development, 2022, 36, 582-600.	5.9	9
6	Adverse events associated with potential drugs for COVID-19: a case study from real-world data. Briefings in Bioinformatics, 2021, 22, 1232-1238.	6.5	10
7	AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Molecular Cancer Research, 2021, 19, 485-497.	3.4	32
8	Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. Journal of Thoracic Oncology, 2021, 16, 439-451.	1.1	34
9	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. Journal of Thoracic Oncology, 2021, 16, 127-139.	1.1	48
10	HeRA: an atlas of enhancer RNAs across human tissues. Nucleic Acids Research, 2021, 49, D932-D938.	14.5	27
11	Small non-coding RNAs in human cancer: function, clinical utility, and characterization. Oncogene, 2021, 40, 1570-1577.	5.9	33
12	Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC. Cancer Research, 2021, 81, 1398-1412.	0.9	16
13	Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. Journal of the National Cancer Institute, 2021, 113, 1396-1404.	6.3	56
14	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell, 2021, 39, 346-360.e7.	16.8	422
15	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. Journal of Thoracic Oncology, 2021, 16, 583-600.	1.1	62
16	Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nature Communications, 2021, 12, 2606.	12.8	41
17	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. Journal of Thoracic Oncology, 2021, 16, 1821-1839.	1.1	34
18	Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. Journal of Thoracic Oncology, 2021, 16, 2051-2064.	1.1	6

#	Article	IF	Citations
19	Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature, 2021, 597, 732-737.	27.8	185
20	Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. Cancer & Metabolism, 2021, 9, 33.	5.0	20
21	Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer. JCI Insight, 2021, 6, .	5.0	12
22	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 1965-1976.	4.2	14
23	Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity. Cancer Cell, 2021, 39, 1558-1559.	16.8	22
24	The EMT activator ZEB1 accelerates endosomal trafficking to establish a polarity axis in lung adenocarcinoma cells. Nature Communications, 2021, 12, 6354.	12.8	20
25	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nature Communications, 2021, 12, 6655.	12.8	24
26	Profiling of immune features to predict immunotherapy efficacy. Innovation(China), 2021, 3, 100194.	9.1	13
27	APAatlas: decoding alternative polyadenylation across human tissues. Nucleic Acids Research, 2020, 48, D34-D39.	14.5	41
28	tRic: a user-friendly data portal to explore the expression landscape of tRNAs in human cancers. RNA Biology, 2020, 17, 1674-1679.	3.1	18
29	Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nature Communications, 2020, 11, 4946.	12.8	120
30	Characterization of the dual functional effects of heat shock proteins (HSPs) in cancer hallmarks to aid development of HSP inhibitors. Genome Medicine, 2020, 12, 101.	8.2	31
31	A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Science Translational Medicine, 2020, 12, .	12.4	101
32	Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. Nature Communications, 2020, 11, 4520.	12.8	218
33	Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biology, 2020, 21, 271.	8.8	36
34	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. , 2020, 8, e000405.		33
35	The genetic and pharmacogenomic landscape of snoRNAs in human cancer. Molecular Cancer, 2020, 19, 108.	19.2	17
36	STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. Journal of Thoracic Oncology, 2020, 15, 777-791.	1.1	94

#	Article	IF	Citations
37	A Multi-Omics Perspective of Quantitative Trait Loci in Precision Medicine. Trends in Genetics, 2020, 36, 318-336.	6.7	41
38	Sex-associated molecular differences for cancer immunotherapy. Nature Communications, 2020, 11, 1779.	12.8	144
39	Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers. Ecancermedicalscience, 2020, 14, 1155.	1.1	6
40	Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer. Nature Communications, 2019, 10, 4562.	12.8	165
41	Comprehensive characterization of circular RNAs in ~‰1000 human cancer cell lines. Genome Medicine, 2019, 11, 55.	8.2	116
42	Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. Journal of Thoracic Oncology, 2019, 14, 2152-2163.	1.1	80
43	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell, 2019, 36, 444-457.e7.	16.8	145
44	Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. Nature Metabolism, 2019, 1, 431-444.	11.9	158
45	ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Science Translational Medicine, 2019, 11, .	12.4	42
46	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discovery, 2019, 9, 646-661.	9.4	555
47	Single-cell reconstruction of differentiation trajectory reveals a critical role of ETS1 in human cardiac lineage commitment. BMC Biology, 2019, 17, 89.	3.8	31
48	High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. , 2019, 7, 351.		39
49	Pancan-meQTL: a database to systematically evaluate the effects of genetic variants on methylation in human cancer. Nucleic Acids Research, 2019, 47, D1066-D1072.	14.5	45
50	CircView: a visualization and exploration tool for circular RNAs. Briefings in Bioinformatics, 2019, 20, 745-751.	6.5	42
51	Myeloid loss of Beclin 1 promotes PD-L1hi precursor B cell lymphoma development. Journal of Clinical Investigation, 2019, 129, 5261-5277.	8.2	25
52	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	6.4	245
53	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Modern Pathology, 2018, 31, 947-955.	5.5	56
54	Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 246-257.	1.1	14

#	Article	IF	Citations
55	Comprehensive Characterization of Alternative Polyadenylation in Human Cancer. Journal of the National Cancer Institute, 2018, 110, 379-389.	6.3	111
56	Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Human Pathology, 2018, 77, 121-129.	2.0	20
57	The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. Cell Systems, 2018, 6, 314-328.e2.	6.2	183
58	PancanQTL: systematic identification of cis-eQTLs and trans-eQTLs in 33 cancer types. Nucleic Acids Research, 2018, 46, D971-D976.	14.5	191
59	Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer. Nature Communications, 2018, 9, 4589.	12.8	57
60	Global analysis of tRNA and translation factor expression reveals a dynamic landscape of translational regulation in human cancers. Communications Biology, 2018, 1, 234.	4.4	58
61	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discovery, 2018, 8, 1548-1565.	9.4	422
62	CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discovery, 2018, 8, 1156-1175.	9.4	323
63	THO Complex-Dependent Posttranscriptional Control Contributes to Vascular Smooth Muscle Cell Fate Decision. Circulation Research, 2018, 123, 538-549.	4.5	25
64	The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. Journal of Clinical Investigation, 2018, 128, 1267-1282.	8.2	48
65	Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget, 2018, 9, 14268-14284.	1.8	12
66	Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of <i>RICTOR/KRAS</i>-altered non-small cell lung cancer. Oncotarget, 2018, 9, 33995-34008.	1.8	9
67	A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Science Advances, 2017, 3, e1600957.	10.3	10
68	A Pan-cancer Analysis of the Expression and Clinical Relevance of Small Nucleolar RNAs in Human Cancer. Cell Reports, 2017, 21, 1968-1981.	6.4	186
69	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Î²-blockers. Science Translational Medicine, 2017, 9, .	12.4	96
70	Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 6239-6253.	7.0	93
71	LNCediting: a database for functional effects of RNA editing in lncRNAs. Nucleic Acids Research, 2017, 45, D79-D84.	14.5	111
72	AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Molecular Cancer Research, 2017, 15, 45-58.	3.4	73

#	Article	IF	Citations
73	Integrated MicroRNA–mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer. International Journal of Molecular Sciences, 2017, 18, 194.	4.1	18
74	Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. OncoImmunology, 2016, 5, e1234570.	4.6	23
75	Selecting Reliable mRNA Expression Measurements across Platforms Improves Downstream Analysis. Cancer Informatics, 2016, 15, CIN.S38590.	1.9	2
76	INO80 governs superenhancer-mediated oncogenic transcription and tumor growth in melanoma. Genes and Development, 2016, 30, 1440-1453.	5.9	65
77	KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. Clinical Cancer Research, 2016, 22, 1940-1950.	7.0	15
78	Hsp90 Inhibitor Ganetespib Sensitizes Non–Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation. Clinical Cancer Research, 2016, 22, 5876-5886.	7.0	25
79	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Research, 2016, 76, 999-1008.	0.9	451
80	Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clinical Cancer Research, 2016, 22, 3630-3642.	7.0	353
81	MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Modern Pathology, 2016, 29, 330-346.	5.5	33
82	Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 1674-1686.	7.0	41
83	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clinical Cancer Research, 2016, 22, 609-620.	7.0	388
84	Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0152584.	2.5	65
85	Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating *BRAF* mutations. Oncotarget, 2016, 7, 565-579.	1.8	31
86	drexplorer: A tool to explore dose–response relationships and drug–drug interactions. Bioinformatics, 2015, 31, 1692-1694.	4.1	22
87	In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation. Molecular Therapy - Nucleic Acids, 2015, 4, e270.	5.1	63
88	TANRIC: An Interactive Open Platform to Explore the Function of lncRNAs in Cancer. Cancer Research, 2015, 75, 3728-3737.	0.9	518
89	Co-occurring Genomic Alterations Define Major Subsets of *KRAS*-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery, 2015, 5, 860-877.	9.4	696
90	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. Clinical Cancer Research, 2015, 21, 3480-3491.	7.0	48

#	Article	IF	Citations
91	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell, 2015, 28, 515-528.	16.8	426
92	Focal adhesion kinase. Cancer Biology and Therapy, 2014, 15, 919-929.	3.4	42
93	Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelialâ€"mesenchymal transition. BMC Genomics, 2014, 15, 1079.	2.8	45
94	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature Communications, 2014, 5, 5241.	12.8	780
95	A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2014, 13, 2738-2750.	4.1	72
96	Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nature Biotechnology, 2014, 32, 644-652.	17.5	257
97	The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. Nature Communications, 2014, 5, 3963.	12.8	143
98	A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nature Communications, 2014, 5, 3887.	12.8	456
99	Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer. Journal of Cancer, 2014, 5, 696-705.	2.5	103
100	An Epithelialâ€"Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. Clinical Cancer Research, 2013, 19, 279-290.	7.0	848
101	Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 6322-6328.	7.0	171
102	Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. Cancer Discovery, 2012, 2, 798-811.	9.4	432
103	Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence. Journal of Thoracic Oncology, 2010, 5, 1894-1904.	1.1	57
104	Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 6852-6861.	7.0	105